{"id":"arq-092","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting mTORC1/2, ARQ 092 blocks the PI3K/AKT/mTOR signaling pathway, which is involved in cell growth and proliferation. This leads to anti-tumor effects by inhibiting protein synthesis and inducing apoptosis in cancer cells.","oneSentence":"ARQ 092 is a potent and selective inhibitor of mTORC1/2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:20.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT04980872","phase":"PHASE2","title":"A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-02","conditions":"PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)","enrollment":60},{"nctId":"NCT03094832","phase":"PHASE1, PHASE2","title":"Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)","status":"TERMINATED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2017-05-16","conditions":"PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome","enrollment":50},{"nctId":"NCT02594215","phase":"PHASE1","title":"Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2015-11-16","conditions":"Proteus Syndrome","enrollment":6},{"nctId":"NCT03317366","phase":"","title":"Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies","status":"NO_LONGER_AVAILABLE","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"","conditions":"Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders","enrollment":""},{"nctId":"NCT02476955","phase":"PHASE1","title":"Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole","status":"TERMINATED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2015-06-09","conditions":"Solid Tumors, Ovarian Cancer, Endometrial Cancer","enrollment":41},{"nctId":"NCT01473095","phase":"PHASE1","title":"Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2011-11","conditions":"Solid Tumor, Malignant Lymphoma, Tumor","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARQ 092","genericName":"ARQ 092","companyName":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","companyId":"arqule-inc-a-subsidiary-of-merck-sharp-dohme-llc-a-subsidiary-of-merck-co-inc-ra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARQ 092 is a potent and selective inhibitor of mTORC1/2. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}